Dermorphin: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store lyophilized powder at -20C protected from light and moisture. Reconstituted solutions should be stored at -80C in single-use aliquots. Avoid repeated freeze-thaw cycles. Working solutions are stable for several hours at room temperature.
Protocol Quick-Reference
Potent mu-opioid receptor agonist for pain research (preclinical only)
Dosing
Amount
0.5-2 nmol intrathecal; 0.01-0.1 nmol ICV; 0.1-5 mg/kg subcutaneous (reduced potency)
Frequency
Single dose or as needed in research protocols
Duration
Single administration studies; not intended for repeated dosing protocols
Administration
Route
SCSchedule
Single dose or as needed in research protocols
Timing
As needed for analgesic testing in research settings
Cycle
Duration
Single administration studies; not intended for repeated dosing protocols
Repeatable
Single cycle
Course-based protocol with rest periods
Preparation & Storage
Diluent: Sterile water
Storage: Store lyophilized powder at -20C protected from light and moisture. Reconstituted solutions should be stored at -80C in single-use aliquots. Avoid repeated freeze-thaw cycles. Working solutions are stable for several hours at room temperature.
๐ก Key Considerations
- โIt cannot cross the blood-brain barrier when administered peripherally, making subcutaneous/IV routes far less potent than central administration
- โHave naloxone (opioid antagonist) immediately available
- โHandle with extreme caution - wear PPE including gloves and eye protection
- โContraindication: Not intended for human use; extreme potency makes accidental exposure dangerous; naloxone must be immediately available during any handling
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Preclinical analgesia (intrathecal) | 0.1-10 nmol | Single dose or as needed in research protocols | Single administration studies | Intrathecal route used to bypass blood-brain barrier; extreme potency requires precise dosing |
| Preclinical analgesia (intracerebroventricular) | 0.01-1.0 nmol | Single dose | Single administration studies | Direct CNS administration; lower doses required compared to intrathecal |
| Receptor binding studies (in vitro) | 0.1-100 nM concentrations | Variable per experimental design | Typically 30-120 minute incubation | Used as radioligand ([3H]dermorphin) or competing ligand |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Reconstitute lyophilized dermorphin in sterile water or physiological saline. Prepare stock solutions at 1 mM concentration. Dilute to working concentrations immediately before use. Due to extreme potency, use appropriate safety precautions during handling.
Recommended Injection Sites
- โIntrathecal (preclinical research)
- โIntracerebroventricular (preclinical research)
- โIntraperitoneal (preclinical research, reduced potency)
๐งStorage Requirements
Store lyophilized powder at -20C protected from light and moisture. Reconstituted solutions should be stored at -80C in single-use aliquots. Avoid repeated freeze-thaw cycles. Working solutions are stable for several hours at room temperature.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Research Dosing Disclaimer#
Dermorphin is a research compound that has not been approved for human use by any regulatory agency. No human dosing guidelines exist. The information below is derived exclusively from preclinical animal studies and is provided for educational and research reference purposes only.
Preclinical Dosing Data#
Intrathecal Administration#
The majority of in vivo analgesic studies with dermorphin have employed intrathecal (spinal) administration to deliver the peptide directly to the central nervous system, bypassing the blood-brain barrier. In rats, intrathecal dermorphin produces dose-dependent analgesia at doses of 0.1 to 10 nmol, with ED50 values typically in the range of 0.5 to 2 nmol depending on the pain model used.
In the classic tail-flick assay, intrathecal dermorphin at 1 nmol produces maximal or near-maximal antinociception in rats, with effects lasting 60 to 120 minutes. For comparison, equianalgesic intrathecal morphine doses are typically 10 to 100 nmol, illustrating dermorphin's 30- to 100-fold greater potency by this route.
Intracerebroventricular Administration#
When administered directly into the cerebral ventricles, dermorphin is even more potent than via the intrathecal route. Analgesic ED50 values by ICV injection are typically 0.01 to 0.1 nmol in rats, reflecting the direct access to supraspinal pain-modulating circuits. The duration of action following ICV administration is generally 30 to 90 minutes for analgesic effects.
Systemic Administration#
Systemically administered dermorphin (intraperitoneal, subcutaneous, or intravenous) is substantially less potent than centrally administered dermorphin due to limited blood-brain barrier penetration. Intraperitoneal doses of 1 to 10 mg/kg have been used in some rodent studies, but the analgesic potency by this route is much lower relative to central administration. This pharmacokinetic limitation has been a major barrier to the development of dermorphin as a systemically administered therapeutic agent.
Dose-Response Characteristics#
Dermorphin exhibits classic opioid dose-response characteristics with a steep dose-response curve for analgesia. In most test paradigms, the maximal analgesic effect (ceiling) is achieved within a 10-fold dose range above the threshold dose. Effects at supranalgesic doses include respiratory depression, sedation, and catalepsy.
| Route | Species | Analgesic ED50 | Duration | Reference Context |
|---|---|---|---|---|
| Intrathecal | Rat | 0.5-2 nmol | 60-120 min | Tail-flick, hot plate tests |
| ICV | Rat | 0.01-0.1 nmol | 30-90 min | Tail-flick test |
| ICV | Mouse | 0.05-0.5 nmol | 30-60 min | Hot plate, writhing tests |
| IP | Mouse | 1-10 mg/kg | 30-60 min | Reduced potency; BBB limitation |
Handling and Preparation#
Reconstitution#
Dermorphin is supplied as a lyophilized powder with purity typically greater than 95% by HPLC. For reconstitution:
- Allow the vial to equilibrate to room temperature before opening
- Add sterile, deionized water or physiological saline to prepare a stock solution (recommended: 1 mM)
- Gently swirl to dissolve; do not vortex vigorously
- Aliquot into single-use volumes and store at -80 degrees C
- Dilute to working concentrations immediately before experimental use
Safety Precautions#
Given dermorphin's extreme potency as an opioid agonist, researchers should observe the following precautions:
- Wear appropriate personal protective equipment including gloves, lab coat, and eye protection
- Handle in a fume hood or well-ventilated area
- Avoid inhalation of powder or aerosols
- Have naloxone available as an emergency opioid antagonist
- Follow institutional guidelines for handling potent opioid compounds
- Properly dispose of waste solutions according to institutional protocols
Storage Recommendations#
- Lyophilized powder: -20 degrees C, desiccated, protected from light; stable for at least 12 months
- Stock solutions (1 mM in water): -80 degrees C in aliquots; stable for approximately 6 months
- Working solutions: Prepare fresh daily; stable for several hours at room temperature and physiological pH
- Avoid repeated freeze-thaw cycles, which may reduce peptide concentration through adsorption to container walls
Cross-Tolerance Considerations#
Researchers should note that animals with prior exposure to morphine or other mu-opioid agonists will exhibit cross-tolerance to dermorphin, requiring higher doses to achieve equivalent analgesic effects. Conversely, dermorphin-tolerant animals show reduced sensitivity to morphine and other mu-agonists. This cross-tolerance pattern is consistent with the shared mu-opioid receptor mechanism.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Dermorphin
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.